The company, which is focused on developing minimally invasive transcervical medical devices, plans to use the financing to expand commercial operations. Combined with its April 2023 funding, Gynesonics has raised $67.2 million, according to a Nov. 1 Gynesonics news release.
The company’s flagship product, the Sonata System, is an FDA-cleared device for the treatment of uterine fibroids.
“With more than 275 million U.S. covered lives (including 19 of the top 20 commercial payers) covering Sonata and our new Category 1 code going live in January, we are excited to accelerate our commercial efforts in the U.S. as well as Europe,” Gynesonics CEO and President Skip Baldino, said in the news release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
